← Back to Screener
C4 Therapeutics, Inc. (CCCC)
Price$2.90
Favorite Metrics
Price vs S&P 500 (26W)25.61%
Price vs S&P 500 (4W)1.61%
Market Capitalization$282.00M
All Metrics
Book Value / Share (Quarterly)$2.65
P/TBV (Annual)0.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)4.95%
Cash Flow / Share (Quarterly)$-1.02
Price vs S&P 500 (YTD)48.67%
Net Profit Margin (TTM)-292.08%
EPS (TTM)$-1.36
10-Day Avg Trading Volume4.36M
EPS Excl Extra (TTM)$-1.36
Revenue Growth (5Y)1.60%
EPS (Annual)$-1.27
ROI (Annual)-40.92%
Net Profit Margin (5Y Avg)-364.35%
Cash / Share (Quarterly)$2.56
Revenue Growth QoQ (YoY)112.79%
ROA (Last FY)-29.24%
Revenue Growth TTM (YoY)1.02%
EBITD / Share (TTM)$-1.37
ROE (5Y Avg)-41.87%
Operating Margin (TTM)-320.53%
Cash Flow / Share (Annual)$-1.02
P/B Ratio1.10x
P/B Ratio (Quarterly)0.72x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)5.77x
Net Interest Coverage (TTM)-46.66x
ROA (TTM)-33.85%
EPS Incl Extra (Annual)$-1.27
Current Ratio (Annual)7.81x
Quick Ratio (Quarterly)7.60x
3-Month Avg Trading Volume2.29M
52-Week Price Return134.96%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.39
P/S Ratio (Annual)7.84x
Asset Turnover (Annual)0.10x
52-Week High$3.82
Operating Margin (5Y Avg)-385.07%
EPS Excl Extra (Annual)$-1.27
CapEx CAGR (5Y)-1.36%
26-Week Price Return29.60%
Quick Ratio (Annual)7.60x
13-Week Price Return35.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.81x
Enterprise Value$207.398
Revenue / Share Growth (5Y)-10.87%
Asset Turnover (TTM)0.12x
Book Value / Share Growth (5Y)-16.48%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-291.74%
Cash / Share (Annual)$2.56
3-Month Return Std Dev98.53%
Net Income / Employee (TTM)$-1
ROE (Last FY)-40.92%
Net Interest Coverage (Annual)-88.52x
EPS Basic Excl Extra (Annual)$-1.27
Receivables Turnover (TTM)13.06x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.36
Receivables Turnover (Annual)13.06x
ROI (TTM)-53.83%
P/S Ratio (TTM)7.84x
Pretax Margin (5Y Avg)-362.97%
Revenue / Share (Annual)$0.43
Tangible BV / Share (Annual)$5.91
Price vs S&P 500 (52W)105.13%
Year-to-Date Return51.31%
5-Day Price Return2.12%
EPS Normalized (Annual)$-1.27
ROA (5Y Avg)-28.17%
Net Profit Margin (Annual)-292.08%
Month-to-Date Return9.89%
Cash Flow / Share (TTM)$-2.71
EBITD / Share (Annual)$-1.37
Operating Margin (Annual)-320.53%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-41.42%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.36
P/TBV (Quarterly)0.35x
P/B Ratio (Annual)0.72x
Pretax Margin (TTM)-291.74%
Book Value / Share (Annual)$2.65
Price vs S&P 500 (13W)34.99%
Beta2.88x
P/FCF (Annual)5.20x
Revenue / Share (TTM)$0.31
ROE (TTM)-53.83%
52-Week Low$1.09
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CCCCC4 Therapeutics, Inc. | 7.84x | 1.02% | — | — | $2.90 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies designed to address difficult-to-treat cancers and other diseases. Its proprietary TORPEDO platform enables the efficient design of small-molecule degraders that leverage the body's natural protein recycling system to overcome drug resistance and tackle undruggable targets. The company's pipeline includes three oncology programs: Cemsidomide, CFT1946, and CFT8919.